PMID- 37722934
OWN - NLM
STAT- MEDLINE
DCOM- 20231113
LR  - 20231115
IS  - 1471-499X (Electronic)
IS  - 1471-4914 (Linking)
VI  - 29
IP  - 12
DP  - 2023 Dec
TI  - Monoamines' role in islet cell function and type 2 diabetes risk.
PG  - 1045-1058
LID - S1471-4914(23)00194-6 [pii]
LID - 10.1016/j.molmed.2023.08.009 [doi]
AB  - The two monoamines serotonin and melatonin have recently been highlighted as 
      potent regulators of islet hormone secretion and overall glucose homeostasis in 
      the body. In fact, dysregulated signaling of both amines are implicated in beta-cell 
      dysfunction and development of type 2 diabetes mellitus (T2DM). Serotonin is a 
      key player in beta-cell physiology and plays a role in expansion of beta-cell mass. 
      Melatonin regulates circadian rhythm and nutrient metabolism and reduces insulin 
      release in human and rodent islets in vitro. Herein, we focus on the role of 
      serotonin and melatonin in islet physiology and the pathophysiology of T2DM. This 
      includes effects on hormone secretion, receptor expression, genetic variants 
      influencing beta-cell function, melatonin treatment, and compounds that alter 
      serotonin availability and signaling.
CI  - Copyright (c) 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.
FAU - Roberts, Fiona Louise
AU  - Roberts FL
AD  - Lund University Diabetes Centre, Department of Clinical Sciences, Unit for 
      Molecular Metabolism, SE-21428 Malmo, Sweden.
FAU - Cataldo, Luis Rodrigo
AU  - Cataldo LR
AD  - Lund University Diabetes Centre, Department of Clinical Sciences, Unit for 
      Molecular Metabolism, SE-21428 Malmo, Sweden; The Novo Nordisk Foundation Centre 
      for Basic Metabolic Research, Faculty of Health and Medical Sciences, University 
      of Copenhagen, Copenhagen, DK-2200, Denmark.
FAU - Fex, Malin
AU  - Fex M
AD  - Lund University Diabetes Centre, Department of Clinical Sciences, Unit for 
      Molecular Metabolism, SE-21428 Malmo, Sweden. Electronic address: 
      malin.fex@med.lu.se.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230916
PL  - England
TA  - Trends Mol Med
JT  - Trends in molecular medicine
JID - 100966035
RN  - JL5DK93RCL (Melatonin)
RN  - 333DO1RDJY (Serotonin)
RN  - 0 (Insulin)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/etiology/metabolism
MH  - *Melatonin/therapeutic use/metabolism
MH  - Serotonin
MH  - Insulin
MH  - *Insulin-Secreting Cells/metabolism
MH  - Glucose/metabolism
OTO - NOTNLM
OT  - G protein-coupled receptors
OT  - insulin secretion
OT  - type 2 diabetes mellitus
OT  - beta-cell dysfunction
COIS- Declaration of interests The authors declare no competing interests.
EDAT- 2023/09/19 00:43
MHDA- 2023/11/13 06:43
CRDT- 2023/09/18 21:52
PHST- 2023/06/27 00:00 [received]
PHST- 2023/08/22 00:00 [revised]
PHST- 2023/08/25 00:00 [accepted]
PHST- 2023/11/13 06:43 [medline]
PHST- 2023/09/19 00:43 [pubmed]
PHST- 2023/09/18 21:52 [entrez]
AID - S1471-4914(23)00194-6 [pii]
AID - 10.1016/j.molmed.2023.08.009 [doi]
PST - ppublish
SO  - Trends Mol Med. 2023 Dec;29(12):1045-1058. doi: 10.1016/j.molmed.2023.08.009. 
      Epub 2023 Sep 16.